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Ack family non-receptor tyrosine kinases are unique with regard to their domain composition and regulatory properties. Human
Ack1 (activated Cdc42-associated kinase) is ubiquitously expressed and is activated by signals that include growth factors and
integrin-mediated cell adhesion. Stimulation leads to Ack1 autophosphorylation and to phosphorylation of additional residues
in the C-terminus. The N-terminal SAM domain is required for full activation. Ack1 exerts some of its eﬀects via protein-
protein interactions that are independent of its kinase activity. In the basal state, Ack1 activity is suppressed by an intramolecular
interaction between the catalytic domain and the C-terminal region. Inappropriate Ack1 activation and signaling has been
implicated in the development, progression, and metastasis of several forms of cancer. Thus, there is increasing interest in Ack1 as
a drug target, and studies of the regulatory properties of the enzyme may reveal features that can be exploited in inhibitor design.
1.Introduction
The mammalian nonreceptor tyrosine kinases (NRTKs) are
dividedintotenfamilies:Src,A bl,J ak,A ck,Csk,Fak,Fes,Frk,
Tec, and Syk [1]. In addition to their tyrosine kinase catalytic
domains, they all contain noncatalytic domains that are
important in enzyme regulation and substrate recognition
[2]. Like all eukaryotic protein kinases, NRTK catalytic
domains have an N-terminal lobe (N-lobe) that contacts
ATP, and a larger C-terminal lobe (C-lobe). The activation
state of the tyrosine kinases depends on the orientation of
an alpha helix (αC) located in the N-lobe. In the active
conformation, the αC helix projects inward toward the ATP-
binding site [3] .T h ec o n f o r m a t i o no faﬂ e x i b l es e g m e n t
in the C-lobe (the activation loop) also has a key role in
the regulation of the enzyme activity [4]. The regulatory
importance of the phosphorylation of the activation loop
varies in the diﬀerent families of NRTKs. For instance, Src
activationisstronglydependentonautophosphorylation[5],
while Csk lacks the autophosphorylation site [6].
Thecontributionsofthenoncatalyticdomainstoenzyme
regulationarewellunderstoodinthecaseoftheSrc-familyof
NRTKS. These enzymes have an N-terminal myristoylation
site followed by an SH3 domain, an SH2 domain, and a
kinase domain. Two tyrosine residues are important for their
activity: Tyr 416 in the activation loop and Tyr 527 in the C-
terminal tail. Structural studies showed the spatial arrange-
ment of Src domains in the inactive state, in which the
noncatalytic domains mediate intramolecular interactions
that maintain the enzyme in a closed, inactive conformation.
In this conformation, the SH3 domain is bound to a proline-
rich helix located between the SH2 domain and the kinase
domain, and the SH2 domain is bound to the phosphory-
lated Tyr 527 [7, 8]. Activating signals provided by protein-
protein interactions that destabilize these intramolecular
interactions may be of three types [2]: the binding of
the SH3 domain to a proline-rich motif (SH3 binding
domain) [9]; the dephosphorylation of the Tyr527 in the C-
terminal tail [10]; the binding of the SH2 domain to other
phospho-Tyr containing proteins [11]. These signals disrupt
the intramolecular inhibition and activate the enzyme. In
addition, the noncatalytic domains provide surfaces for
diﬀerent types of interactions that couple the activation of
the catalytic domain to substrate recognition [2, 12, 13].
The mechanisms involved in enzymatic regulation vary
among the diﬀerent families of NRTKs. For example, Abl2 Journal of Signal Transduction
kinases have similar arrangements of domains as Src-family
kinases, but the regulatory mechanisms are diﬀerent; this has
important implications for the design of pharmacological
inhibitors [3]. In both Src- and Abl-family NRTKS, the SH3
domain interacts with a poly-proline helix in the linker
region between the SH2 domain. In contrast to Src, the
SH2 domain of Abl interacts in a phospho-Tyr independent
manner with the C-terminal lobe of the kinase domain.
An additional diﬀerence is that an N-terminal cap and
a myristoyl group wrap around the base of the kinase
domain of Abl and stabilize the inhibited structure [14].
Importantly, the conformation of the inhibited activation
loop is unique to the c-Abl catalytic domain. The inhibitor
Imatinib (Gleevec) has been particularly successful due to its
ability to target this conformation [14].
As new structures of NRTKs are solved, new molecular
mechanisms for enzyme regulation are revealed. Structural
studies have illuminated the contributions of noncatalytic
domains to the regulation of Syk- [3, 5], Csk- [6, 15–
17], and Fes-family kinases [3]. The speciﬁc roles of the
noncatalytic regions vary among these kinases. For instance,
in Csk and Fes kinases, interactions between the SH2 and
the catalytic domains stabilize the active conformation [3].
In general, the noncatalytic domains of all NRTKs are likely
to participate in subcellular localization, autoregulation, and
substrate targeting.
2.Ack FamilyKinases
The domain architecture of human Ack1 (also called Tnk2)
is shown in Figure 1 (top). Ack1 is a 120kDa protein with
an N-terminal sterile alpha motif (SAM) domain [18], a
kinasedomain,anSH3domain,andaCdc42/Rac-interactive
domain (CRIB) [19]. Several functionally relevant regions
have been identiﬁed in the C-terminal region of Ack1:
multiple proline-rich sequences, a clathrin-binding motif
[20], an ubiquitin binding domain [21], and a region that
shares a high homology with Mig6 [22]. The Ack family
kinases have a unique domain arrangement. They are the
only NRTKs with the SH3 domain located C-terminal to
the kinase domain, and they are also the only tyrosine
kinases with a CRIB domain. In view of its unique domain
composition, the regulatory features of Ack1 are likely to
diﬀer from those observed in other NRTKs.
Ack1 belongs to a family of NRTKs that includes human
Tnk1, and homologous proteins in mouse, cow, Drosophila
melanogaster, and Caenorhabditis elegans [23, 24]. Although
all the members share the overall domain architecture shown
in Figure 1 (i.e., kinase domain and SH3 domain), there are
major diﬀerences in the C-terminal regions of the proteins.
Furthermore, Tnk1, DACK (from Drosophila), and Kos1
(from mouse) lack CRIB domains [24].
Ack1, the ﬁrst member of the Ack family, was cloned
from a human hippocampal expression library by its ability
tobindGTP-boundCdc42speciﬁcallyandnotRac1orRhoA
[19]. The gene encoding Ack1 is located on chromosome
3q29 in humans, a region that is associated with recurrence
of prostate cancer and is a predictor of metastatic relapse in
breast cancer [25].
Tnk1 (thirty-eight-negative kinase 1) was originally
cloned from hematopoietic stem/progenitor cells from
umbilical cord blood in humans [26]. Tnk1 is a member of
the Ack family with a predicted size of 72kDa and the same
domain architecture as Ack for the region common to both
familymembers[26].Kos1isthemurinehomologueofTnk1
[27]. In contrast with the other members of the Ack family
(namely, Ack1/Tnk2, Ack2, and DPR2), but similarly to
DACK,Tnk1,andKos1lacktheCRIBdomain[24,27].Tnk1,
was found to be speciﬁcally expressed in umbilical blood
and not other hematopoietic tissues and to interact with
phospholipase C-γ1 through its proline-rich region [28]. It
hasbeenreportedthatduringembryonicdevelopment,Tnk1
blocks NF-κB activation and thereby promotes apoptosis
mediated by the TNFα signaling pathway [29]. Kos1 is a
47kDa protein that was cloned from diﬀerentiating murine
embryonic stem cells [27]. The Kos1 gene is located in
chromosome 11 in mice and it is thought to be a murine
splice variant of the human Tnk1 [27]. Tnk1/Kos1 have been
reported to have proapoptotic or tumor-suppressor func-
tions. Kos1 inhibits Ras activation and negatively regulates
cell growth [27]. Tnk1/Kos1 knockout in mice results in an
increased rate of tumor development [30].
Ack2 was ﬁrst cloned from a bovine brain expression
library. Ack2 has a predicted size of 83kDa and contains
the same basic domain structure as Ack1. Ack2 is thought
to be an isoform of Ack1 that is generated by alternative
splicing and is not encoded by a diﬀerent gene [18]. The
Ack2 C-terminal region contains a 15-residue insert and has
344 fewer amino acids than Ack1 [31]. In humans there
is no evidence for the existence of an Ack2 homologue
[18, 25]. However, a number of the experimental studies
on Ack (activation pathways, biochemical properties, and
biological roles) focused on Ack2, and they will be discussed
throughout this paper.
In Drosophila, there are two members of the Ack family:
DACK and DPR2. The roles of DPR2 and DACK have not
been dissected but they are thought to be diﬀerent because
DPR2 has a Cdc42-binding domain, while DACK lacks
one. Cdc42 regulates the expression of DACK in Drosophila
embryos [24]. The tyrosine kinase activity of DACK has been
implicateddownstreamofCdc42inthepathwaythatleadsto
dorsal closure of the epidermis during embryogenesis [24].
In C. elegans, Ark-1 (A Ras-regulating Kinase 1), a cytoplas-
mic tyrosine kinase that is related to Ack1, acts as a negative
regulator of EGFR signaling. In a yeast two-hybrid analysis,
Ark-1 interacts with the Grb2 homologue, Sem5 [23].
The degree of conservation of the full-length sequences
varies among the family members. The common core that
is conserved in all of the Ack family members spans from
the N-terminus to the SH3 domain. The amino acid identity
of this core (compared with Ack1) ranges between 100%
for Ack2 and 29% for Kos1 (Figure 1). The Ack1 kinase
domain itself shares ≈ 40% amino acid identity with other
nonreceptor and receptor tyrosine kinases. Phylogenetic
analyses of human tyrosine kinase catalytic domains place
Ack1 near epidermal growth factor receptor (EGFR) family
kinases [32, 33]. As described below, Ack1 and EGFR may
also share aspects of enzymatic regulation.Journal of Signal Transduction 3
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Figure 1: Ack family kinases. Domain arrangement of the members of the Ack family discussed in this paper. The diﬀerent proteins are
arranged in decreasing order of identity to the common core (Nt-Kinase-SH3).
3.ActivationPathways
Expression of Ack1 has been demonstrated in several tissues
in mammals, with the highest expression in spleen, thymus,
and brain [18]. A number of stimuli, including EGF,
PDGF [18], bradykinin [31], agonists of the M3 muscarinic
receptor [34], and integrin-mediated cell adhesion [35, 36]
promote phosphorylation and activation of Ack1.
Upon EGF stimulation, Ack1 phosphorylates and acti-
vates the guanine exchange factor Dbl. Ack1 interacts with
the Rho-family GTPase Cdc42 and the adaptor protein Grb2
andtheseinteractionsareessentialforthispathway[37].The
association of Ack1 with Grb2 has been shown in several
studies through diﬀerent approaches. In vitro studies showed
that Ack1 associates with several SH3 domains, including the
SH3 domain from Grb2 [38]. Ack1 association with multiple
receptor tyrosine kinases such as Axl, LTK, and ALK is also
dependent on Grb2 [39].
Ack is involved in integrin β1-mediated signaling path-
ways that modulate processes such as cell migration, cell
adhesion, and cell spreading. Ack2 is present in a complex
with integrin β1; it is activated by cell adhesion to a
ﬁbronectin-coated surface in a Cdc42-dependent manner
and it activates the phosphorylation of Jnk [36]. In response
to Cdc42 activation, Ack1 mediates the phosphorylation of
p130Cas to promote cell migration [35, 40]. Ack1 is found in
a complex with Cas, Crk, and Cdc42 in collagen-stimulated
cells [35]. Cas appears to be an important adaptor protein
downstream of Ack1 in these pathways. A signaling complex
composed of Cdc42, Ack1, and Cas also participates in
the regulation of melanoma cell spreading by melanoma
chondroitin sulphate proteoglycan (MCSP), a proteoglycan
that is expressed on the surface of melanoma cells [40]. The
expression of Ack2 in HeLa cells increases cell migration in a
mechanism that also involves p130Cas and CrkII [41]. Thus,
one of the physiological functions of Ack1 appears to be
related to the regulation of cell adhesion and cell migration.
ThesestudiesalsosuggestthatAck1activityisinvolvedinthe
development of metastatic potential of transformed cells.
Several studies have focused on the role of Ack1 in
EGF receptor traﬃcking and dynamics. Ack1 is recruited
to EGFR following EGF stimulation [21]. EGFR stability
and recycling are regulated by interactions between Ack1
and multiple protein partners including ubiquitin [21],
clathrin heavy chain [20, 42], and SH3PX1 [43, 44]. In HeLa
cells, overexpression of Ack1 inhibits EGFR endocytosis and
causes the accumulation of EGF in internal structures of
endocytic origin, suggesting that Ack1 is involved in the
intracellular sorting of activated EGFR [45]. The knock-
down of Ack1 increases the rate of recycling 125I-EGF
to the plasma membrane and reduces the degradation of
125I-EGF, suggesting that Ack1 promotes degradation of
EGFR [45]. In Cos7 cells, overexpression of Ack1 promotes
EGFR degradation by binding to the ubiquitinated EGF
receptor [21]. Increased stability of Ack1 caused by a somatic
mutation (S985N) in the ubiquitin binding domain (UBA)
results in defective EGFR downregulation and sustained
activation of downstream signaling [46].4 Journal of Signal Transduction
In addition to the eﬀect of Ack1 on receptor stability and
dynamics, there is a reciprocal eﬀect on Ack1 stability. After
receptor stimulation by EGF, Ack1 is recruited to an EGFR
complex [21, 47]. This complex promotes the activation of
Ack1 [18] and EGFR degradation [21, 45, 46, 48]a sw e l l
as Ack1 turnover [49, 50]. The EGF-induced degradation of
Ack1 is signaled by ubiquitination [49, 50]. The details of
this mechanism are still under study. In one report, the E3
UbiquitinligaseNedd4-2wasshowntoubiquitinatetheUBA
domain of Ack1 and induce its degradation by proteasomes
[49]. In a second report, the E3 Ligase Nedd4-1 was
demonstrated to ubiquitinate the Ack1 SAM domain, while
the deletion of the UBA domain enhanced ubiquitination. In
these experiments, the degradation of Ack1 was mediated by
lysosomesratherthanbyproteasomes[50].Inbothcases,the
WW domains of the E3 ligases bound to a conserved PPXY
motif in Ack1.
4. Biochemical and Regulatory
Properties of Ack1
There is currently no crystal structure of full-length Ack1.
The crystal structure of the isolated kinase domain of
Ack1 has been solved in both phosphorylated and unphos-
phorylated forms. In these structures, the activation loop
conformations are similar and do not occlude the substrate-
binding site, suggesting that the phosphorylation of the
activation loop may not play a dramatic stimulatory role
[59]. The only other structural information available is for
the isolated CRIB domain of Ack1 in a complex with Cdc42
[60]. In the absence of a structure of full-length Ack1,
biochemical experiments have helped to reveal how each of
the domains contributes to Ack1 function.
A major autophosphorylation site has been mapped to
the Y284 in the activation loop [38]. A construct containing
residues 1- 476, corresponding to the N-terminus, the kinase
domain, the SH3 domain, and the CRIB domain (Nt-
Kinase-SH3-CRIB) is the longest construct that has been
puriﬁed to homogeneity [38]. This construct is activated,
although modestly (3-fold), by the phosphorylation of Y284.
Proteomicapproacheshaveidentiﬁedotherphosphorylation
sites in Ack1. In BCR-ABL transformed cell lines, Y826,
Y856, and Y857 of Ack1 are phosphorylated [51] (Figure 2).
The phosphorylation of Y826 was also identiﬁed in a study
of phosphorylated proteins downstream of insulin signaling
[52]. Y857 of Ack1 was identiﬁed in a mass spectrometry
study in which protein phosphorylation events downstream
of the EGFR-family member HER2 were analyzed [53]. In
addition, the phosphorylation of Y518 was identiﬁed in a
study of global tyrosine phosphorylation patterns in cancer
cells [54]. The biological signiﬁcance of these phosphory-
lation sites remains to be determined. Interestingly, Y826,
Y857, and Y858 are located in the Mig6-homology region
(MHR), a portion of Ack1 that participates in inhibitory
intramolecular interactions [58]. It is possible that the MHR
of Ack1 is a substrate for oncogenic BCR-ABL, or for insulin
and EGF receptors, resulting the release of autoinhibition.
Relatively little information is available about the regu-
latory mechanisms of Ack1 and the roles that each domain
plays in Ack1 regulation. The puriﬁed Nt-Kinase-SH3-CRIB
polypeptide is active in vitro and can be used in enzymatic
assays [38]. The peptide substrates that are the most
eﬃciently phosphorylated by this construct are EAIYAAP-
FAKKKG (Abl consensus substrate) or KVIYDFIEKKKKG
(peptide derived from WASP tyrosine phosphorylation site)
[61]. In addition to this tyrosine kinase activity, Ack1
acts as a dual-speciﬁcity kinase towards WASP and the
phosphorylation of a serine residue of WASP (Wiskott-
Aldrich syndrome protein) increases the ability of WASP to
polymerize actin [62]. Ligands for the SH3 domain and the
CRIB domain bind to this construct, but fail to activate it,
although addition of Cdc42 in vivo does increase Ack1 Y284
phosphorylation[38].Residuesimportantfortheinteraction
betweenAck1andCdc42havebeenidentiﬁedfromtheNMR
structure of the complex formed by a peptide spanning the
residues 548–489 of Ack1 (CRIB domain is 548–475) and
Cdc42 [60].
One way of studying the role of each domain in Ack1
regulation is to assess the eﬀects of point mutations on the
enzyme’s phosphorylation state (Figure 2). A mutation that
occursinovarianendometrioidcarcinoma(E346K)hasbeen
helpful to gain insight into the role of the Mig6 homology
region (MHR). These studies have suggested that there is
an autoinhibitory interaction between the C-lobe of Ack1
kinase domain and the MHR [58]. Mutations such as V365R
(in the kinase domain) or F820A and E346K (in the MHR)
destabilize this conformation and activate Ack1 [58]. Ack is
activated by additional cancer-associated mutations located
in the SAM domain (R34L and R99Q), and in the SH3
domain (M409I), but the mechanism is not clear. Several
studies have produced a constitutively active Ack1 by the
point mutation of L487F in the CRIB domain [56, 57]. The
position of this mutation is thought to be analogous to
L107F in Pak1, which is known to prevent an autoinhibitory
interaction [63]. However, it is not known whether the CRIB
domain of Ack1 participates in autoinhibition. A mutation
designed to prevent the binding of the SH3 domain to its
ligand (W426K) was reported to produce activation of Ack1
[18]. In contrast, a point mutation that disrupts Cdc42
binding (H464D) reduced Ack1 autophosphorylation [18].
The deletion of the N-terminal SAM domain reduced
Ack1 autophosphorylation and kinase activity [18, 64].
The SAM domain has the potential to drive Ack1 to
the plasma membrane [18, 64] and to form dimers or
multimers that increase the local concentration in order to
stimulate Ack1 activation [64]. Interestingly, the deletion of
the Ack1 SAM domain also prevented EGF-induced Ack1
ubiquitination, consistent with the requirement of the SAM
domain for activation [64] and with the observation that
Ack1 is ubiquitinated after activation [50]. These results
suggest that the individual domains of Ack1 are involved
in regulatory interactions that could be either inter- or
intramolecular. The downregulated state of Ack1 involves
the intramolecular interaction of the MHR with the kinase
domain (Figure 3(a)). As a result of a stimulatory signal,
provided by activated EGFR, one or more tyrosine residues
located in the Ack1 MHR are phosphorylated (Figure 3(b)).
These phosphorylation events may promote Ack1 activationJournal of Signal Transduction 5
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Figure 2: Residues important for Ack1 function. Phosphorylation sites are indicated in black. Tyr284 is the major site of
autophosphorylation [38]. Tyr518, Tyr826, Tyr857, and Tyr858 were identiﬁed in proteomic studies [51–54]. Cancer-associated mutations
a r ei nb l u e[ 55]. Point mutations reported to aﬀect Ack1 autophosphorylation are shown in green [18, 56, 57]. The numbering scheme used
corresponds to the accession number Q07912.
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Figure 3: A model for Ack1 regulation. (a), the downregulated
state of Ack1 is stabilized by an intramolecular interaction of the
Mig6 homology region (MHR) with the kinase domain [58]. (b),
the activated conformation is depicted when bound to the plasma
membrane or an internal membrane. Stimulatory signals can be of
three types: binding of GTP-bound Cdc42 to the CRIB domain,
binding of poly-proline containing sequences (PP) to the SH3
domain, or phosphorylation of the MHR by activated receptors
such as EGFR. The SAM domain is required for membrane local-
izationandmaximalactivity.Uponactivation,Ack1phosphorylates
downstream substrates such as p130Cas or WASP and modulates
cell adhesion and cell migration. Ack1 promotes tumorigenesis by
phosphorylating Wwox, Akt, and Androgen receptor. Yellow circles
represent phosphorylation sites.
bydestabilizingtheautoinhibitedconformation.Inaddition,
the SAM domain of Ack1 is required for full autophosphory-
lation and activation of Ack1. It is not clear whether the SAM
domain participates in autoinhibition but as noted above, it
is involved in subcellular targeting and required for maximal
enzymatic activity.
The domain composition of Ack1 is complex and it is
likely that in the future, additional interactions (both intra-
and intermolecular) will be described that will explain in
more detail the molecular mechanisms of Ack1 regulation
and signaling.
5. The Role of Ack1 in Cancer
Ack1 has been implicated in several stages and several
types of cancer; this topic has been reviewed recently in
[65]. Early experiments demonstrated that a peptide derived
from the Ack1 CRIB domain blocked the Ras-mediated
transformation of NIH-3T3 cells [66]. Ack1 expression
was later shown to be required for the survival of cells
transformed by v-Ras [67].
In a study of ∼180 advanced-stage cancers, 9% of the
lung tumors and 14% of the ovary tumors had an ampliﬁca-
tion of the Ack1 gene on chromosome 3. In addition, 42% of
the aggressive lung tumors and 77% of metastatic hormone
refractory prostate tumors showed overexpression of the
Ack1 mRNA. Ack1 overexpression enhanced migration of
human mammary epithelial cells (HMECs) and increased
metastasis in the mouse mammary 4T1 breast cancer system
[25]. Moreover, activation of Ack1 by overexpression of
Ack1 produced several epithelial-to-mesenchymal transition
(EMT) phenotypes in the human breast cancer cell line
MDA-MB-231. In renal cancer cells, activation of Ack1 by
a somatic point mutation also resulted in EMT phenotypes
[46]. Thus, activation of Ack1 is associated with poor
prognosis and metastatic phenotypes in human tumors [25].
In addition, the knockdown of Ack1 in breast cancer cells
inhibits cell migration [47]. This suggests a role for Ack1 as
a metastasis determinant, perhaps as a modiﬁer of other pre-
metastatic lesions.
The mechanistic basis of Ack1’s involvement in prostate
tumorigenesis has been explored in detail. In the cultured
prostate cancer cell line LNCaP, the tumor suppressor Wwox6 Journal of Signal Transduction
is phosphorylated and marked for degradation by Ack1 [57].
The androgen receptor (AR) is a transcriptional activator
that plays important roles in the development of advanced
stage (androgen-independent) prostate cancer. Activated
Ack1 has been shown to phosphorylate and activate AR
function and to promote the progression of prostate cancer
[68]. In addition, Ack1 Tyr284 phosphorylation was recently
found to correlate with disease progression and proposed to
be prognostic of progression of prostate cancer [69].
A large-scale study that screened cancer tissues for
somatic mutations identiﬁed four missense mutations in
Ack1 [55]. In lung adenocarcinoma and ovarian carcinoma,
two mutations located in the N-terminus (R34L and R99Q,
resp.) were identiﬁed; in ovarian endometrioid carcinoma,
a mutation in the kinase catalytic domain (E346K) was
identiﬁed; and in lung adenocarcinoma, a mutation in the
SH3domain(M409I)wasfound(Figure2).Thefourcancer-
associated mutations activate Ack1 and promote anchorage
independent growth and cell migration [58]. An additional
somatic mutation found in renal cancer, S985N, located
in the UBA domain of Ack1, increases Ack1 stability and
enhances oncogenic signaling through EGFR [46].
The functions of Ack1 in cancer cells appear to be of
two types: kinase-independent and kinase-dependent. The
eﬀect of Ack1 on cell proliferation is independent of Ack1
activity [58]. In a phosphoproteomic study of the action of
the antitumor drug dasatinib in lung cancer, Ack1 emerged
as a signaling node that represents a possible target in cancer
treatment. This study highlighted a possible scaﬀolding
function of Ack1 in the context of control of cell growth
[70]. In contrast, the activation state of Ack1 appears to be
important in processes that involve enhanced cell motility,
that are crucial in the metastatic stage of cancer progression
and correlate with poor prognosis [25, 58, 67]. In breast
cancer, Ack1 phosphorylates and promotes the activation of
Akt, an important mediator of signaling pathways that lead
to transformation [71].
6. Known LigandsandSubstratesof Ack1
A number of Ack1 substrates have been identiﬁed in normal
c e l l sa sw e l la sc a n c e rc e l l s .P h o s p h o r y l a t i o no fW A S Pb y
Ack1promotesitsactinremodelingactivity[62].Inaddition,
p130Cas is phosphorylated by Ack1, promoting cell spread-
ing [40] and cell migration [35]. These results, together with
the enhanced migration of cells overexpressing Ack1 [25]o r
expressing an activated form of Ack1 [58], suggest that Ack1
plays a role in the regulation of cell adhesion and migration.
Ack1 also phosphorylates androgen receptor (AR), increas-
ing the levels of phosphorylated AR in prostate cancer and
promoting AR-mediated gene transcription [68, 69].
A comprehensive list of known Ack1 substrates and
interacting proteins was recently published [65], and it
includes diverse molecules involved in signaling such as
receptor tyrosine kinases (MERK, EGFR, PDGFR, AXL,
ALK,andLTK),membraneproteins(integrin,MCSP),adap-
tor molecules (Grb2, HSH2), nucleotide exchange factors
(Dbl), a transcription activator (AR), a tumor suppressor
(Wwox), and a proto-oncogene (Akt/PKB). Other Ack1
interactors include proteins involved with vesicle dynamics
(clathrin, SNX9) and cytoskeleton remodeling (WASP). A
number of SH3 containing proteins, such as Hck [38], Grb2,
and SNX9 [44, 72] have been identiﬁed as ligands for the
proline rich region of Ack1. Recently, the E3 ubiquitin ligases
Nedd4-1 and Nedd4-2 were shown to bind to a PPXY motif
of Ack1 and to regulate its proteolytic degradation [49, 50].
7. Conclusions
Nonreceptortyrosinekinasesshareseveralcommonfeatures.
The NRTK catalytic domains never occur in isolation; they
are tethered to noncatalytic modular domains that play
important roles in enzymatic function. The biochemical
properties of the individual noncatalytic domains are similar
to those found in other signaling proteins. However, the
regulatory mechanisms are diverse and vary between the
diﬀerent families of NRTKs. To date, 15 out of the 32 NRTKs
in the human genome have been shown to have oncogenic
potential [1]. Consequently, NRTKs represent signiﬁcant
targets for the development of inhibitors. Activation of Ack1
(by overexpression or mutation) promotes migration and
EMT and correlates with cancer progression. Thus, Ack1
has emerged as a candidate for anti cancer drug design;
Ack1 inhibitors could potentially be used in combination
therapies with inhibitors of other tyrosine kinases, such
as EGFR. Knowledge about NRTK regulatory mechanisms
can be exploited for the development of speciﬁc inhibitory
drugs. For example, imatinib inhibits Abl (but not Src)
because it binds to a speciﬁc conformation of Abl that Src
is not capable of adopting [73]. Moreover, the inhibited
conformation of Abl appears to be the result of the interplay
ofthenoncatalyticdomains[73].Ack1isregulatedbyanovel
mechanism that shares basic principles with other NRTKs
but also has unique features dictated by its unusual domain
structure. Investigations into the regulatory mechanisms and
conformational states of Ack1 will be an important prelude
to the development of speciﬁc Ack1 inhibitors.
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